# OnKure

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/onkure

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.onkuretherapeutics.com
- Total disclosed funding: $88M
- Latest round: Series C (Mar 24, 2023)
- Investors on record: 9

## About

OnKure, Inc. is a biopharmaceutical company dedicated to the discovery and development of precision medicines targeting cancer. Its innovative focus lies in tumor-agnostic therapies designed to improve patient outcomes.OnKure, Inc. specializes in developing targeted cancer treatments. Founded in 2011 in Boulder, US, the company has undergone significant growth with seven deals to date, the most recent being a Series C round on March 24, 2023. The company was co-founded by Anthony Piscopio and Xuedong Liu, with Anthony Piscopio currently serving as CEO. It has raised a total of USD 53.783 mn in funding, which reflects its strategic plans for innovation in oncology therapies.OnKure Therapeutics specializes in the discovery and development of precision medicines targeted at cancer treatment. Their core product offerings focus on tumor-agnostic oncology therapies that can be effective across various types of tumors. The company is advancing next-generation therapies that address significant unmet medical needs in the cancer treatment landscape. OnKure’s products aim to enhance patient outcomes by precisely targeting cancer cells while minimizing effects on healthy tissue, serving healthcare providers and research institutions primarily in North America and Europe.OnKure Therapeutics generates revenue through strategic partnerships and collaborations within the biopharmaceutical industry, engaging in B2B transactions with healthcare institutions and pharmaceutical partners. Revenue streams involve milestone payments from drug development phases and royalties from successful commercialized therapies, in line with industry standards for proprietary oncology medications. The company's flagship products, aimed at treating various forms of cancer, play a central role in their revenue generation strategy and reflect their commitment to precision medicine.On March 24, 2023, OnKure, Inc. raised USD 53.78 million in Series C funding, led by Surveyor Capital with participation from several returning investors, including Acorn Bioventures and BlackRock. This funding will be utilized to further develop OnKure’s pipeline of precision medicines and move the OKI-219 discovery program into the clinical stage. The company is also planning to expand its market presence in North America and Europe, targeting new healthcare institutions by the end of 2024.

## Funding rounds

- Series C, Mar 24, 2023, $54M — Surveyor Capital, BlackRock, Cormorant Asset Management, Perceptive Advisors, Samsara BioCapital, Acorn Bioventures, Deep Track Capital
- Series B, Mar 4, 2021, $29M — Solebury Capital, Surveyor Capital, BlackRock, Cormorant Asset Management, Perceptive Advisors, Samsara BioCapital, Acorn Bioventures
- Series A, Feb 6, 2018, $5M — Delian Capital

## Investors

- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series A
- Solebury Capital (https://capitalatlas.ai/funds/solebury-capital) — Series B
- Surveyor Capital — Series B, Series C
- BlackRock (https://capitalatlas.ai/funds/blackrock) — Series B, Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B, Series C
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B, Series C
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series B, Series C
- Acorn Bioventures (https://capitalatlas.ai/funds/acorn-bioventures) — Series B, Series C
- Deep Track Capital (https://capitalatlas.ai/funds/deep-track-capital) — Series C